US-based Cold Spring Harbor Laboratory (CSHL) has collaborated with British drugmaker GlaxoSmithKline (GSK) to develop a treatment for obesity and type 2 diabetes.
The partnership will identify potent, selective and orally bioavailable small molecules that inhibit PTP1B activity in-vivo following stimulation by insulin and leptin to overcome resistance encountered in diabetes and obesity.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the multi-year deal, CSHL and GSK scientists will carry out drug development based on a new approach to regulate the enzymatic activity of the phosphatase PTP1B.
CSHL business development and technology transfer vice-president Teri Willey said: "At CSHL, we are striving to achieve mutually beneficial and effective collaborations to accelerate research and develop new therapies to benefit patients."
The partnership will identify potent, selective and orally bioavailable small molecules that inhibit PTP1B activity in-vivo following stimulation by insulin and leptin to overcome resistance encountered in diabetes and obesity.
Dr Nicholas Tonks will be head of the research work at CSHL, who is proficient on the protein tyrosine phosphatase (PTP) family of enzymes and their roles in human diseases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGSK The Discovery Partnership with Academia programme (DPAc) global head Carolyn Buser said: "At GSK, we believe that combining the in-depth target and disease knowledge of renowned academic groups with our drug-discovery expertise and capabilities can foster innovation and speed-up the discovery and development of new medicines.
"We are excited to expand our partnerships in North America and look forward to working closely with Dr Tonks, whose deep understanding of protein tyrosine phosphatase biology will complement our own work in this field."
Diabetes had a worldwide prevalence of 366 million in 2011 and is expected to increase to 552 million by 2030, as per the International Diabetes Federation.
Image: Structural representation of the PTP1B enzyme, showing reduced and oxidised forms. Photo: courtesy of Cold Spring Harbor Laboratory.
